GlassScriptPhysician profile
Naveena Allada
NPI 1184826992
$5,511.42
in general payments reported to CMS, 2019-2025
46 companies · $2,886 in 2025
The $2,886 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $30.99 · 2021: $133 · 2022: $573 · 2023: $633 · 2024: $1,110 · 2025: $2,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,483 · Long Term Medical Supply Or Device Loan: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,482.90 |
| Long Term Medical Supply Or Device Loan | $2,145.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,562.37 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $249.40 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Pfizer INC. | $229.26 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $197.15 | 2021-2023 | Myrisk |
| Celgene Corporation | $193.99 | 2019-2025 | Reblozyl, Opdualag |
| Regeneron Healthcare Solutions, INC. | $156.46 | 2022-2024 | Libtayo |
| Gilead Sciences, INC. | $144.86 | 2021-2025 | Trodelvy |
| Abbvie INC. | $135.59 | 2019-2025 | |
| Adc Therapeutics America, INC. | $123.69 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.10 | 2025 | Fruzaqla, Iclusig |
| Eisai INC. | $89.58 | 2022-2023 | |
| Astellas Pharma US INC | $85.76 | 2025 | Vyloy |
| Array Biopharma INC | $80.45 | 2025 | Mektovi, Xalkori, Lorbrena |
| Astrazeneca Pharmaceuticals LP | $72.69 | 2023-2025 | Imfinzi, Calquence |
| Incyte Corporation | $67.14 | 2023-2025 | Jakafi |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveena Allada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.